Drugs / Beloranib
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01507077 | Dec 2011 → Mar 2012 | obesity disorder | Zafgen, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01372761 | Jun → Nov 2011 | obesity disorder | Zafgen, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01028261 | Dec 2009 → Oct 2010 | obesity disorder | Zafgen, Inc. | Completed | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT02324491 | Dec 2014 → Dec 2015 | obesity disorder, type 2 diabetes mellitus | Zafgen, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02063295 | Apr → Nov 2014 | brain injury, craniopharyngioma, obesity disorder | Zafgen, Inc. | Completed | Met primary |
| Phase 2 | NCT01818921 | Jun → Nov 2013 | Prader-Willi syndrome, obesity disorder | Zafgen, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01666691 | Aug 2012 → May 2013 | obesity disorder | Zafgen, Inc. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02179151 | Sep 2014 → Dec 2015 | Prader-Willi syndrome, obesity disorder | Zafgen, Inc. | Terminated | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beloranib | “The purpose of this study is to assess the Pharmacokinetics/Pharmacodynamics (PK/PD), safety, and effectiveness of multiple subcutaneous doses of Beloranib (ZGN-440).” NCT01507077 ↗4“The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adult subjects with type 2 diabetes mellitus.” NCT02324491 ↗ “Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.” NCT01818921 ↗ “Beloranib treatment was associated with improvements in high-sensitivity CRP.” PMID 28261955 ↗ Apr 2017 |
| Known as | ZGN-433 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01028261 ↗ |
| Known as | ZGN-440 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02179151 ↗ |
| Action | Inhibit | “a Novel Methionine Aminopeptidase 2 Inhibitor” NCT01507077 ↗ |
| Modality | Small molecule | — CHEMBL4297504 ↗ |
| Route | Intravenous | “Intravenous Doses of ZGN-433” NCT01372761 ↗ |
| Target | METAP2 | “A Novel Methionine Aminopeptidase 2 Inhibitor” NCT02063295 ↗ |